Entropic Consequences of Linking Ligands

Fragment-based Approaches in Drug Discovery

Volumn 34, Issue , 2006, Pages 55-66

  Murray, Christopher W ^a   Verdonk, Marcel L ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

Analysis; Concept; Drug discovery; Entropic consequences of linking ligands; Estimate of rigid body barrier to binding; Experimental examples of fragment linking; Fragment linking; Rigid body barrier to binding; Theory

Indexed keywords

FREE ENERGY; LIGANDS; RIGID STRUCTURES;

ANALYSIS; CONCEPT; DRUG DISCOVERY; FRAGMENT LINKING; RIGID BODY; THEORY;

BINDING ENERGY;

EID: 84870998578     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608761.ch3     Document Type: Chapter

References (23)

1. Jencks, W. P. 1981, On the attribution and additivity of binding energies, Proc. Natl. Acad.Sci.USA 78, 4046-4050.
2. Page, M. I., Jencks, W. P. 1971, Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect, Proc. Natl. Acad. Sci.USA 68, 1678-1683.
3. Page, M. I. 1973, The energetics of neigh-bouring group participation, Chem. Soc. Rev. 2, 295-323.
4. Dill, K. A. 1997, Additivity principles in biochemistry, J.Biol.Chem. 272, 701-704.
5. Finkelstein, A. V., Janin, J. 1989, The price of lost freedom: entropy of bimolecular complex formation, Protein Eng. 3, 1-3.
6. Gilson, M. K., Given, J. A., Bush, B. L., Mccammon, J. A. 1997, The statistical-thermodynamic basis for computation of binding affinities: a critical review, Biophys. J. 72, 1047-1069.
7. Searle, M. S., Williams, D. H. 1992, Partitioning of free energy contributions in the estimation of binding constants: residual motions and consequences for amide-amide hydrogen bond strengths, J.Am.Chem.Soc. 114, 10690-10704.
8. Murray, C. W., Verdonk, M. L. 2002, The consequences of translational and rotational entropy lost by small molecules on binding to proteins, J. Comput. Aided Mol.Des. 16, 741-753.
9. Mammen, M., Shakhnovich, E. I., Whitesides, G. M. 1998, Using a convenient, quantitative model for torsional entropy to establish qualitative trends for molecular processes that restrict conformational freedom, J.Org.Chem. 63, 3168-3175.
10. Erlanson, D. A., McDowell, R. S., O'Brien, T. 2004, Fragment-based drug discovery, J. Med. Chem. 47, 3463-3482.
11. Rees, D. C., Congreve, M., Murray, C. W., Carr, R. 2004, Fragment-based lead discovery, Nat. Rev. Drug Discov. 3, 660-672.
12. Hanessian, S., Lu, P. P., Sanceau, J. Y., Chemla, P., Gohda, K., Fonne-Pfister, R., Prade, L., Cowan-Jacob, S. W. 1999, An enzyme-bound bisubstrate hybrid inhibitor of adenylosuccinate synthetase, Angew. Chem. Int. Ed. Engl. 38, 3159-3162.
13. Poland, B. W., Lee, S. F., Subramanian, M. V., Siehl, D. L., Anderson, R. J., Fromm, H. J., Honzatko, R. B. 1996, Re-fined crystal structure of adenylosucci-nate synthetase from Escherichia coli complexed with hydantocidin 5'-phosphate, GDP, HPO4(2-), Mg2+, and hadacidin, Biochemistry 35, 15753-15759.
14. Fonne-Pfister, R., Chemla, P., Ward, E., Girardet, M., Kreuz, K. E., Honzatko, R. B., Fromm, H. J., Schar, H. P., Grutter, M. G., Cowan-Jacob, S. W. 1996, The mode of action and the structure of a herbicide in complex with its target: binding of activated hydantocidin to the feedback regulation site of adenylosuccinate synthetase, Proc. Natl. Acad. Sci.USA 93, 9431-9436.
15. Hajduk, P. J., Shuker, S. B., Nettesheim, D. G., Craig, R., Augeri, D. J., Betebenner, D., Albert, D. H., Guo, Y., Meadows, R. P., Xu, L., Michaelides, M., Davidsen, S. K., Fesik, S. W. 2002, NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability, J. Med. Chem. 45, 5628-5639.
16. Rath, V. L., Ammirati, M., Danley, D. E., Ekstrom, J. L., Gibbs, E. M., Hynes, T. R., Mathiowetz, A. M., McPherson, R. K., Olson, T. V., Treadway, J. L., Hoover, D. J. 2000, Human liver glycogen phosphorylase inhibitors bind at a new allosteric site, Chem. Biol. 7, 677-682.
17. Olejniczak, E. T., Hajduk, P. J., Marcotte, P. A., Nettesheim, D. G., Meadows, R. P., Edalji, R., Holzman, T. F., Fesik, S. W. 1997, Stromelysin inhibitors designed from weakly bound fragments: effects of linking and cooperativity, J. Am. Chem. Soc. 119, 5828-5832.
18. Hopkins, A. L., Groom, C. R., Alex, A. 2004, Ligand efficiency: a useful metric for lead selection, Drug Discov. Today 9, 430-431.
19. Hajduk, P. J., Sheppard, G., Nettesheim, D. G., Olejniczak, E. T., Shuker, S. B., Meadows, R. P., Steinman, D. H., Carrera, G. M., Jr., Marcotte, P. A., Severin, J., Walter, K., Smith, H., Gubbins, E., Simmer, R., Holzman, T. F., Morgan, D. W., Davidsen, S. K., Summers, J. B., Fesik, S. W. 1997, Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR, J. Am. Chem. Soc. 119, 5818-5827.
20. Green, N. M. 1975, Avidin, Adv. Protein Chem. 29, 85-133.
21. Schaschke, N., Matschiner, G., Zettl, F., Marquardt, U., Bergner, A., Bode, W., Sommerhoff, C. P., Moroder, L. 2001, Bivalent inhibition of human beta-tryptase, Chem. Biol. 8, 313-327.
22. Rao, J., Whitesides, G. M. 1997, Tight binding of a dimeric derivative of vancomycin with dimeric L-Lys-D-Ala-D-Ala, J. Am. Chem. Soc. 119, 10286-10290.
23. Rao, J., Lahiri, J., Isaacs, L., Weis, R. M., Whitesides, G. M. 1998, A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin. biotin, Science 280, 708-711.